0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Neurological Review |

Supportive Care for Patients With Guillain-Barré Syndrome FREE

Richard A. C. Hughes, MD; Eelco F. M. Wijdicks, MD; Estelle Benson; David R. Cornblath, MD; Angelika F. Hahn, MD; Jay M. Meythaler, MD; John T. Sladky, MD; Richard J. Barohn, MD; James C. Stevens, MD
[+] Author Affiliations

Financial Disclosure: Dr Cornblath has consulted for Pfizer Inc, who makes Neurontin (gabapentin), and Ortho-McNeil Pharmaceutical Inc, who makes Ultram (tramadol).


Section Editor: David E. Pleasure, MD

More Author Information
Arch Neurol. 2005;62(8):1194-1198. doi:10.1001/archneur.62.8.1194.
Text Size: A A A
Published online

A multidisciplinary consensus group searched MEDLINE from 1966 to May 2003, extracted relevant references, and prepared recommendations on supportive care for Guillain-Barré syndrome. In the absence of randomized controlled trials, we agreed on recommendations by consensus based on observational studies and expert opinion. In the acute phase in bed-bound adult patients, the group recommended the use of heparin and graduated pressure stockings to prevent deep vein thrombosis, monitoring for blood pressure, pulse, autonomic disturbances, and respiratory failure, and the timely institution of artificial ventilation and tracheostomy. Pain management is difficult, but carbamazepine or gabapentin may help. The cautious use of narcotic analgesics may be needed. Disabled patients should be treated by a multidisciplinary rehabilitation team and should receive an assistive exercise program. Persistent fatigue following Guillain-Barré syndrome is common and may be helped by an exercise program. Because of a very small and possibly only theoretical increase in the risk of recurrence following immunization, the need for immunization should be reviewed on an individual basis. More research is needed to identify optimal methods for all aspects of supportive care.

A recent practice parameter recommended either intravenous immunoglobulin or plasma exchange, but not corticosteroids, as appropriate treatments for adults and probably children with severe Guillain-Barré syndrome (GBS) within 2 weeks from onset.1 Most patients in the trials of these treatments have had the demyelinating form of the disease, and the benefits of treatment in uncommon subgroups, such as those with axonal disease, cannot be distinguished. Despite immunotherapy, 4% to 15% of patients with GBS die from this syndrome26 and nearly 20% have a persistent disability.5 Death from GBS occurs mostly in mechanically ventilated patients. Supportive care remains the mainstay of treatment, but the evidence for the methods of supportive care is inadequate and consensus guidelines for treatment have not been published.

EVIDENCE REVIEW

The consensus group of 6 neurologists with a special interest in GBS, 1 physical medicine specialist, 1 evidence-based medicine specialist, and 1 patient advocate met and decided which questions to review.

We searched MEDLINE from 1966 onward (last search in May 2003) for articles including the term polyradiculoneuritis, limited by human and cross-referenced with the terms therapy, pain, nutrition, diet, pulmonary ventilation, tracheostomy, artificial respiration, autonomic nervous system, dysautonomia, arrhythmia, neurogenic bladder, urinaryincontinence, urination disorders, constipation, physical therapy, occupational therapy, palliative care, supportive care, thrombophlebitis, immunization, and recurrence. We also searched the Cochrane Library register of randomized trials (issue 3, 2003) with Guillain-Barré syndrome as the search term. Two members of the group prepared draft statements and recommendations that were circulated through the entire group repeatedly until consensus was achieved. Our recommendations are, therefore, consensus statements based on observational studies of GBS, inferences from randomized controlled trials in other conditions, and expert opinion.

PROPHYLAXIS FOR DEEP VEIN THROMBOSIS

Immobilization owing to GBS is a risk factor for the development of deep vein thrombosis (DVT).7 Time to developing DVT or pulmonary embolus varies from 4 to 67 days after onset.7,8 Children have a very low incidence of DVT.9 There is a lack of clinical studies that address methods of prophylaxis against thrombosis in GBS, duration of prophylaxis, or monitoring of patients at risk for thrombosis. Observational studies in orthopedic or general surgery patients suggest a benefit from subcutaneous heparin (5000 U, 12-hourly) in preventing DVT.9 In acutely ill medical patients, prophylactic treatment with subcutaneous enoxaparin (40 mg daily) reduced the incidence of DVT from 15% in the placebo group to approximately 5% in the treated patients.10 In a recent meta-analysis, support stockings reduced the risk by almost 70% in patients at moderate risk for development of postoperative thromboembolism.11

RECOMMENDATION

Subcutaneous unfractionated or fractionated heparin and support stockings are recommended for nonambulant adult patients until they become able to walk independently.

CARDIAC AND HEMODYNAMIC MONITORING

Serious and potentially fatal disturbances of autonomic function, including arrhythmias and extreme hypertension or hypotension, occur in approximately 20% of patients with GBS.12,13 Severe bradycardia may be preceded by wide swings, exceeding 85 mm Hg, of systolic blood pressure from day to day.14 Bradycardia may be so severe as to cause asystole, which may require a cardiac pacemaker.12 Endotracheal suction or pharmaceutical agents may provoke these changes.14,15 Other significant autonomic disturbances in GBS are adynamic ileus, hyponatremia, and deficiencies in bronchial mucosal function. Most, but not all, dysautonomic complications occur among patients with advanced generalized weakness and respiratory failure.16 In 1 prospective study,17 a reduction in beat-to-beat variation in heart rate predicted subsequent dysautonomia.

RECOMMENDATION

Monitoring of pulse and blood pressure is recommended in patients who are becoming severely affected by GBS until they have discontinued the ventilatory support and have had their tracheostomy removed or until they have begun to recover without needing either intervention. The evidence concerning the method and setting of monitoring is insufficient to make specific recommendations.

RESPIRATORY MONITORING AND AIRWAY PROTECTION

Neuromuscular respiratory function becomes compromised in 17% to 30% of patients with GBS.6,16,1821 In some patients, bulbar dysfunction causes difficulty with clearing secretions, compromising gas exchange and increasing the risk of aspiration.2224 Clinical features that indicate fatigue of respiratory muscles are tachypnea, sweating, tachycardia, asynchronous movements of the chest and abdomen, and episodic use of accessory muscles of respiration. In 1 case series,22 rapid disease progression, presence of bilateral facial palsy, and autonomic dysfunction increased the likelihood of intubation. A study of 722 patients, of whom 313 required ventilation, identified 6 predictors of the need for ventilation in a multivariate analysis: time from onset to admission being less than 7 days, inability to cough, inability to stand, inability to flex the arms or head, and liver enzyme level increases.25 In 196 of the patients with available vital capacity measurements, predictors were time from onset to admission being less than 7 days, inability to lift the head, and vital capacity of less than 60% of that which was predicted. In many patients, a vital capacity (measured volume with forceful exhalation after maximal inhalation) below 20 mL/kg, a PImax (maximum inspiratory pressure generated after maximal sucking in through a mouth piece while occluding the nose) of less than 30 cm H2O or a PEmax (maximum expiratory pressure generated on maximal blowing out) of less than 40 cm H2O warns of imminent respiratory arrest.2628 Rapid decline in vital capacity (eg, 50% from baseline) may further indicate impending respiratory failure, but this finding needs confirmation.26,27 Patients with pulmonary infiltrates or atelectasis generally require intubation and mechanical ventilation. Hypoxemia is also an indicator of neuromuscular respiratory failure. Hypercarbia appears later.21 Thus, respiratory failure in GBS is common and life threatening. Emerging diaphragmatic failure can be detected by serial clinical observation or respiratory function tests. Patients who require ventilation are at high risk of suffering major complications including pneumonia, sepsis, gastrointestinal tract bleeding, pulmonary embolus, and others. In a series of 114 patients, 60% admitted to an intensive care unit had major complications in 1 of these categories.29

RECOMMENDATION

Respiratory function should be monitored in patients with GBS, but there is insufficient evidence to recommend specific methods. Weaning from the ventilator should be guided by improvement in strength and serial pulmonary function tests.

TIMING AND METHOD OF TRACHEOSTOMY

The mean duration of ventilation in various treatment trials has ranged between 15 and 43 days, suggesting that a proportion of patients can be spared from receiving a tracheostomy.28,3032 Early tracheostomy increases patient comfort and airway safety and may help weaning. On the other hand, surgical tracheostomy results in permanent disfigurement and has sometimes been associated with life-threatening hemorrhage, infection, accidental dislodgement of the tube, fatal procedure-related necrotizing mediastinitis, chyle fistula due to a thoracic duct perforation, and a cosmetically unacceptable, hypertrophic keloid tracheostomy scar. More recently, percutaneous dilatational tracheostomy has been introduced, but this technique has not been compared with traditional tracheostomy in GBS. In a randomized trial in patients selected for elective tracheostomy, percutaneous dilatational tracheostomy was superior.33 The procedure involves a small skin incision and then insertion of a cannula into the trachea, followed by dilators of gradually increasing size until the desired tracheostomy tube can be accommodated. Percutaneous tracheostomy may reduce the risk of accidental extubation owing to the fact that it fits more snugly around the stoma. A better cosmetic outcome may result from a smaller skin incision.3436

A newly introduced pulmonary function ratio has been used to predict the need for tracheostomy.37 Daily vital capacity and maximal inspiratory and expiratory pressures were summed to create an integrated pulmonary function score. A pulmonary function ratio was calculated, which represents the pulmonary function score at day 12 after intubation divided by the pulmonary function score at the day of intubation. This study found that at day 12 with a pulmonary function ratio of less than 1, it is highly unlikely that patients will be weaned from the ventilator within 3 weeks and tracheostomy should be performed. The sensitivity of a pulmonary function ratio of less than 1 for predicting that the duration of ventilation would be more than 3 weeks was 70%, and the specificity and positive predictive value were 100%.

RECOMMENDATION

The decision to place a tracheostomy may be postponed for 2 weeks. If after 2 weeks the pulmonary function tests do not show any significant improvement from baseline, tracheostomy should be performed. If the pulmonary function test tends to improve above baseline, tracheostomy could be deferred for an additional week, allowing the patient to attempt to be weaned from the ventilator. Percutaneous tracheostomy may be preferred in centers with adequate experience in using the technique.

PAIN MANAGEMENT

Retrospective observational analyses of GBS case series have documented pain as an early symptom, with an incidence ranging from 33% to 71%.3843 One study examined incidence and intensity of pain prospectively and quantified the response to medical pain intervention.41 Pain was reported by 89% of the patients and was severe in half. First-line drugs that were used were acetaminophen and nonsteroidal anti-inflammatory drugs. However, 75% of the patients additionally required oral or parenteral opioids and 30% of the patients were treated with intravenous morphine infusions (range, 1-7 mg/h). Ten percent of the patients received tricyclic antidepressants and a further 10% received carbamazepine as adjuvant treatments for neuropathic pain during the later course of the illness. In a randomized, double-blind, crossover trial involving 18 participants, gabapentin (15 mg/kg daily) or placebo was given by a nasogastric tube for 7 days before switching to the alternate treatment.44 There was prompt substantial and significant relief of pain and reduction in the need for rescue medication. In a similar study45 of 12 patients, greater pain relief was obtained from carbamazepine (300 mg daily for 3 days) than from placebo. Excellent relief of intractable and severe pain by epidural infusions of morphine (1- to 4-mg morphine bolus injections every 8-24 hours) has been reported in a single case study.46 Opioid analgesics may aggravate autonomic gut dysmotility and bladder distention.47,48

RECOMMENDATION

Simple analgesics or nonsteroidal anti-inflammatory drugs may be tried but often do not provide adequate pain relief. Single small randomized controlled trials support the use of gabapentin or carbamazepine in the intensive care unit for the treatment of pain in the acute phase of GBS. Appropriate narcotic analgesics may be used but require careful monitoring of adverse effects in the setting of autonomic denervation. Adjuvant therapy with tricyclic antidepressant medication, tramadol, gabapentin, carbamazepine, or mexilitene may aid in the long-term management of neuropathic pain.

MANAGEMENT OF BLADDER AND BOWEL DYSFUNCTION

Constipation occurs frequently in bed-bound patients. Approximately half of the patients develop adynamic ileus in the acute phase, often but not invariably in conjunction with other features of dysautonomia.47 In other instances, the risk is increased by long-term immobilization, incremental doses of opiates for pain control, or preexisting causes such as prior abdominal procedures.

Bladder function has only been studied infrequently in the acute phase of GBS, partly because most patients are catheterized as part of their general nursing care to maintain bodily hygiene and to avoid bladder distention. Voiding is more frequently compromised with axonal types of GBS. Urodynamic studies have documented bladder areflexia and disturbed bladder sensation.49

RECOMMENDATION

Daily abdominal auscultation for development of gut silence and monitoring of opioid administration are recommended. In addition to suspension of gut-feeding nasogastric and rectal tubes, erythromycin or neostigmine may be effective in treating adynamic ileus.50 Promotility agents are contraindicated in patients with dysautonomia. Bladder catheterization is often needed as part of the intensive care of severely affected patients. A sterile, closed urinary drainage system should be used with avoidance of breaking the seal to obtain urinary samples and irrigation of the bladder.

REHABILITATION

Although most patients with GBS need rehabilitation, there are no long-term rehabilitation outcome studies or comparisons of different methods.51 In neuromuscular disease, overfatiguing the affected motor unit in therapy may impede recovery and cause paradoxical weakening.52,53 Attention needs to be paid to many details that cannot be summarized briefly. There is a danger of muscle shortening and joint contractures.51 Prolonged immobilization leads to a reduction of blood volume and increased episodes of postural hypotension.54 For some immobilized patients, a tilt table has been useful.51 Weight loss and significant sensory loss make patients susceptible to peripheral nerve compression and the development of decubitus ulcers, requiring proper bed positioning with frequent postural changes.51 In patients noted to have immobilization hypercalcemia, early mobilization was correlated with a therapeutic drop in the serum calcium levels.55 In the acute stage, patients lose weight. During recovery, they regain weight owing to reduced activity levels.55,56

RECOMMENDATION

Treatment in the acute phase should include an individual program of gentle strengthening involving isometric, isotonic, isokinetic, and manual resistive and progressive resistive exercises. Rehabilitation should be focused on proper limb positioning, posture, orthotics, and nutrition.

MANAGEMENT OF FATIGUE

A large proportion of patients with GBS remain seriously affected in their psychosocial functioning even when their physical recovery was complete or when they were left with only mild residual signs.57,58 Severe fatigue persists in 80% of patients and is unrelated to age, duration, or severity of the initial illness.59 Frequency and severity of fatigue in GBS were comparable with that encountered in other immune-mediated neuropathies.59,60 The cause and contributing factors are not fully known, but fatigue appears in part to be a sequel of forced inactivity and general muscle deconditioning. Both fatigue and functional abilities were measurably improved with a supervised exercise program in 2 single case studies.52,61 Pharmacological approaches are being evaluated.62,63

RECOMMENDATION

An exercise program may be beneficial for persistent fatigue.

FUTURE IMMUNIZATIONS

Recurrence of GBS after immunization is rare.64 In response to a questionnaire, 11 (3.5%) of 311 patients reported recurrent symptoms within 6 weeks after immunization, but it was possible to deduce with 95% confidence that the chance of developing GBS severe enough to require hospital admission was less than 1.2%.65 In 2 previously reported cases, recurrence occurred following swine influenza vaccine.66 Recurrent attacks of chronic inflammatory demyelinating polyradiculoneuropathy have followed tetanus toxoid immunization.67,68

RECOMMENDATION

Immunizations are not recommended during the acute phase of GBS and probably not during a period, possibly of 1 year, after the onset of the disease. After that, immunizations need not be withheld, but the need for the immunization should be reviewed on an individual basis. If GBS occurs within 6 weeks after a particular immunization, consideration should be given to avoiding that immunization in that individual in the future.

CONCLUSION

This review has highlighted the need for more research into all aspects of supportive care for GBS.

Correspondence: Richard A. C. Hughes, MD, Department of Clinical Neuroscience, King’s College, Guy’s Hospital, London SE1 1UL, England (richard.a.hughes@kcl.ac.uk).

Accepted for Publication: June 15, 2004.

Author Contributions:Study concept and design: Hughes, Wijdicks, Benson, Cornblath, Hahn, Barohn, and Stevens. Acquisition of data: Hughes, Wijdicks, Hahn, Meythaler, Sladky, and Stevens. Analysis and interpretation of data: Hughes, Wijdicks, Cornblath, Hahn, Meythaler, and Stevens. Drafting of the manuscript: Hughes, Wijdicks, Cornblath, Meythaler, and Sladky. Critical revision of the manuscript for important intellectual content: Hughes, Wijdicks, Benson, Cornblath, Hahn, Meythaler, Barohn, and Stevens. Statistical analysis: Stevens. Administrative, technical, and material support: Hughes, Wijdicks, Benson, and Stevens. Study supervision: Hughes and Wijdicks.

Disclaimer: Our recommendations must be interpreted in relation to the needs of the individual patient and the capacity of the individual institution.

Hughes  RACWijdicks  EBarohn  RJ  et al.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61736- 740
PubMed Link to Article
Prevots  DRSutter  RW Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997;175(suppl 1)S151- S155
PubMed Link to Article
Raphael  JCMasson  CMorice  VBronel  DGoulon  M Le syndrome de Guillain-Barré: étude retrospective de 233 observations. Sem Hop Paris 1984;602543- 2546
Rees  JHThompson  RDSmeeton  NCHughes  RAC An epidemiological study of Guillain-Barré syndrome in South East England. J Neurol Neurosurg Psychiatry 1998;6474- 77
PubMed Link to Article
Italian Guillain-Barré Study Group, The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;1192053- 2061
PubMed Link to Article
Chio  ACocito  DLeone  MGiordana  MTMora  GMutani  R Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;601146- 1150
PubMed Link to Article
Lawn  NDWijdicks  EF Fatal Guillain-Barré syndrome. Neurology 1999;52635- 638
PubMed Link to Article
Legere  BMDweik  RAArroliga  AC Venous thromboembolism in the intensive care unit. Clin Chest Med 1999;20367- 384
PubMed Link to Article
Collins  RScrimgeour  AYusuf  SPeto  R Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;3181162- 1173
PubMed Link to Article
Samama  MMCohen  ATDarmon  JY  et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341793- 800
PubMed Link to Article
Clagett  GPReisch  JS Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208227- 240
PubMed Link to Article
Hughes  RAC Guillain-Barré Syndrome.  Heidelberg, Germany: Springer-Verlag; 1990
Ropper  AHWijdicks  EFMTruax  BT Guillain-Barré Syndrome.  Philadelphia, Pa: FA Davis Co; 1991
Pfeiffer  GSchiller  BKruse  JNetzer  J Indicators of dysautonomia in severe Guillain-Barré syndrome. J Neurol 1999;2461015- 1022
PubMed Link to Article
Hughes  RACBihari  D Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry 1993;56334- 343
PubMed Link to Article
Ng  KKPHoward  RSFish  DR  et al.  Management and outcome of severe Guillain-Barré syndrome. QJM 1995;88243- 250
PubMed
Flachenecker  PHartung  HPReiners  K Power spectrum analysis of heart rate variability in Guillain-Barré syndrome: a longitudinal study. Brain 1997;1201885- 1894
PubMed Link to Article
Gracey  DRMcMichan  JCDivertie  MBHoward  FM  Jr Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc 1982;57742- 746
PubMed
Massam  MJones  RS Ventilatory failure in the Guillain-Barré syndrome. Thorax 1980;35557- 558
PubMed Link to Article
Moore  PJames  O Guillain-Barré syndrome: incidence, management, and outcome of major complications. Crit Care Med 1981;9549- 555
PubMed Link to Article
Newton-John  H Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust 1985;142444- 445
PubMed
Lawn  NDFletcher  DDHenderson  RDWolter  TDWijdicks  EFM Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58893- 898
PubMed Link to Article
Ropper  AHKehne  SM Guillain-Barré syndrome: management of respiratory failure. Neurology 1985;351662- 1665
PubMed Link to Article
Chevrolet  JCDeleamont  P Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis 1991;144814- 818
PubMed Link to Article
Sharshar  TChevret  SBourdain  FRaphael  JC Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003;31278- 283
PubMed Link to Article
Sunderrajan  EVDavenport  J The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine 1995;64333- 341
PubMed
Pontoppidan  HGeffin  BLowenstein  E Acute respiratory failure in the adult, 2. N Engl J Med 1972;287743- 752
PubMed Link to Article
McKhann  GMGriffin  JWCornblath  DR  et al.  Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23347- 353
PubMed Link to Article
Henderson  RDLawn  NDFletcher  MDMcClelland  RLWijdicks  EFM The morbidity of Guillain-Barré syndrome admitted to the intensive care unit. Neurology 2003;6017- 21
PubMed Link to Article
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome, Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41298- 306
PubMed Link to Article
French Cooperative Group in Plasma Exchange in Guillain-Barré Syndrome, Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22753- 761
PubMed Link to Article
Guillain-Barré Syndrome Steroid Trial Group, Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341586- 590
PubMed
Holdgaard  HOPedersen  JJensen  RH  et al.  Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy: a clinical randomised study. Acta Anaesthesiol Scand 1998;42545- 550
PubMed Link to Article
Dulguerov  PGysin  CPerneger  TVChevrolet  JC Percutaneous or surgical tracheostomy: a meta-analysis. Crit Care Med 1999;271617- 1625
PubMed Link to Article
Griggs  WMMyburgh  JAWorthley  LI A prospective comparison of a percutaneous tracheostomy technique with standard surgical tracheostomy. Intensive Care Med 1991;17261- 263
PubMed Link to Article
Heffner  JE Percutaneous tracheotomy: novel technique or technical novelty? Intensive Care Med 1991;17252- 253
PubMed Link to Article
Lawn  NDWijdicks  EF Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve 2000;23613- 616
PubMed Link to Article
Haymaker  WKernohan  JW The Landry-Guillain-Barré syndrome: a clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine (Baltimore) 1949;2859- 141
Link to Article
Marshall  J The Landry-Guillain-Barré syndrome. Brain 1963;8655- 66
Link to Article
McFarland  HRHeller  GL Guillain-Barré disease complex. Arch Neurol 1966;14196- 201
PubMed Link to Article
Moulin  DEHagen  NFeasby  TEAmireh  RHahn  A Pain in Guillain-Barré syndrome. Neurology 1997;48328- 331
PubMed Link to Article
Ravn  H The Landry-Guillain-Barré syndrome: a survey and clinical report of 127 cases. Acta Neurol Scand 1967;43(suppl 30)1- 64
PubMed
Winer  JBHughes  RACOsmond  C A prospective study of acute idiopathic neuropathy, I: clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51605- 612
PubMed Link to Article
Pandey  CKBose  NGarg  G  et al.  Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002;951719- 1723
PubMed Link to Article
Tripathi  MKaushik  S Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 2000;28655- 658
PubMed Link to Article
Rosenfeld  BBorel  CHanley  D Epidural morphine treatment of pain in Guillain-Barré syndrome. Arch Neurol 1986;431194- 1196
PubMed Link to Article
Burns  TMLawn  NDLow  PACamilleri  MWijdicks  EF Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve 2001;24963- 965
PubMed Link to Article
Zochodne  DW Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;171145- 1155
PubMed Link to Article
Sakakibara  RHattori  TKuwabara  SYamanishi  TYasuda  K Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;63649- 653
PubMed Link to Article
Ponec  RJSaunders  MDKimmey  MB Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999;341137- 141
PubMed Link to Article
Meythaler  JM Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil 1997;78872- 879
PubMed Link to Article
Pitetti  KHBarrett  PJAbbas  D Endurance exercise training in Guillain-Barré syndrome. Arch Phys Med Rehabil 1993;74761- 765
PubMed Link to Article
Herbison  GJJaweed  MDitunno  JF Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil 1983;64201- 205
PubMed
Johnson  PCFisher  CLLeach  C Hematological implications of hypodynamic states.  In: Murray  RH, McCally  M, eds. Hypogravic and Hypodynamic Environments. Washington, DC: National Aeronautics and Space Administration; 1971:27-34
Meythaler  JMKorkor  ABKumar  NANanda  TFallon  M Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome: successful therapy with combined calcitonin and etidronate. Arch Intern Med 1986;1461567- 1571
PubMed Link to Article
Meythaler  JMDeVivo  MJBraswell  WC Rehabilitation outcomes of patients who have developed Guillain-Barré syndrome. Am J Phys Med Rehabil 1997;76411- 419
PubMed Link to Article
Bernsen  RAJAMJacobs  HMDe Jager  AEJvan der Meché  FGA Residual health status after Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;62637- 640
PubMed Link to Article
Bernsen  RAJAMDe Jager  AEJSchmitz  PIMvan der Meché  FGA Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53409- 410
PubMed Link to Article
Merkies  ISSchmitz  PISamijn  JPvan der Meché  FGvan Doorn  PAEuropean Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Fatigue in immune-mediated polyneuropathies. Neurology 1999;531648- 1654
PubMed Link to Article
Krupp  LBLaRocca  NGMuir-Nash  JSteinberg  AD The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;461121- 1123
PubMed Link to Article
Karper  WB Effects of low-intensity aerobic exercise on one subject with chronic-relapsing Guillain-Barré syndrome. Rehabil Nurs 1991;1696- 98
PubMed Link to Article
Murray  TJ Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12251- 254
PubMed
Garssen  MPJSchmitz  PIMvan der Meché  FGAMerkies  ISJvan Doorn  PA Amantadine for treatment of fatigue after the Guillain-Barré syndrome (GBS), a double-blind, randomized, placebo controlled, cross-over trial. Neuromuscul Disord200212759 . Abstract
Wijdicks  EFMFletcher  DDLawn  DD Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology 2000;55452- 453
PubMed Link to Article
Pritchard  JMukherjee  RHughes  RAC The risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry 2002;73348- 349
PubMed Link to Article
Seyal  MZiegler  DKCouch  JR Recurrent Guillain-Barré syndrome following influenza vaccine. Neurology 1978;28725- 726
PubMed Link to Article
Hughes  RACChoudhary  PPOsborn  MRees  JHSanders  EACM Immunisation and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1996;191230- 1231
PubMed Link to Article
Pollard  JDSelby  G Relapsing neuropathy due to tetanus toxoid. J Neurol Sci 1978;37113- 125
PubMed Link to Article

Figures

Tables

References

Hughes  RACWijdicks  EBarohn  RJ  et al.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61736- 740
PubMed Link to Article
Prevots  DRSutter  RW Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997;175(suppl 1)S151- S155
PubMed Link to Article
Raphael  JCMasson  CMorice  VBronel  DGoulon  M Le syndrome de Guillain-Barré: étude retrospective de 233 observations. Sem Hop Paris 1984;602543- 2546
Rees  JHThompson  RDSmeeton  NCHughes  RAC An epidemiological study of Guillain-Barré syndrome in South East England. J Neurol Neurosurg Psychiatry 1998;6474- 77
PubMed Link to Article
Italian Guillain-Barré Study Group, The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;1192053- 2061
PubMed Link to Article
Chio  ACocito  DLeone  MGiordana  MTMora  GMutani  R Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;601146- 1150
PubMed Link to Article
Lawn  NDWijdicks  EF Fatal Guillain-Barré syndrome. Neurology 1999;52635- 638
PubMed Link to Article
Legere  BMDweik  RAArroliga  AC Venous thromboembolism in the intensive care unit. Clin Chest Med 1999;20367- 384
PubMed Link to Article
Collins  RScrimgeour  AYusuf  SPeto  R Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;3181162- 1173
PubMed Link to Article
Samama  MMCohen  ATDarmon  JY  et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341793- 800
PubMed Link to Article
Clagett  GPReisch  JS Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208227- 240
PubMed Link to Article
Hughes  RAC Guillain-Barré Syndrome.  Heidelberg, Germany: Springer-Verlag; 1990
Ropper  AHWijdicks  EFMTruax  BT Guillain-Barré Syndrome.  Philadelphia, Pa: FA Davis Co; 1991
Pfeiffer  GSchiller  BKruse  JNetzer  J Indicators of dysautonomia in severe Guillain-Barré syndrome. J Neurol 1999;2461015- 1022
PubMed Link to Article
Hughes  RACBihari  D Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry 1993;56334- 343
PubMed Link to Article
Ng  KKPHoward  RSFish  DR  et al.  Management and outcome of severe Guillain-Barré syndrome. QJM 1995;88243- 250
PubMed
Flachenecker  PHartung  HPReiners  K Power spectrum analysis of heart rate variability in Guillain-Barré syndrome: a longitudinal study. Brain 1997;1201885- 1894
PubMed Link to Article
Gracey  DRMcMichan  JCDivertie  MBHoward  FM  Jr Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc 1982;57742- 746
PubMed
Massam  MJones  RS Ventilatory failure in the Guillain-Barré syndrome. Thorax 1980;35557- 558
PubMed Link to Article
Moore  PJames  O Guillain-Barré syndrome: incidence, management, and outcome of major complications. Crit Care Med 1981;9549- 555
PubMed Link to Article
Newton-John  H Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust 1985;142444- 445
PubMed
Lawn  NDFletcher  DDHenderson  RDWolter  TDWijdicks  EFM Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58893- 898
PubMed Link to Article
Ropper  AHKehne  SM Guillain-Barré syndrome: management of respiratory failure. Neurology 1985;351662- 1665
PubMed Link to Article
Chevrolet  JCDeleamont  P Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis 1991;144814- 818
PubMed Link to Article
Sharshar  TChevret  SBourdain  FRaphael  JC Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003;31278- 283
PubMed Link to Article
Sunderrajan  EVDavenport  J The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine 1995;64333- 341
PubMed
Pontoppidan  HGeffin  BLowenstein  E Acute respiratory failure in the adult, 2. N Engl J Med 1972;287743- 752
PubMed Link to Article
McKhann  GMGriffin  JWCornblath  DR  et al.  Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23347- 353
PubMed Link to Article
Henderson  RDLawn  NDFletcher  MDMcClelland  RLWijdicks  EFM The morbidity of Guillain-Barré syndrome admitted to the intensive care unit. Neurology 2003;6017- 21
PubMed Link to Article
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome, Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41298- 306
PubMed Link to Article
French Cooperative Group in Plasma Exchange in Guillain-Barré Syndrome, Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22753- 761
PubMed Link to Article
Guillain-Barré Syndrome Steroid Trial Group, Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341586- 590
PubMed
Holdgaard  HOPedersen  JJensen  RH  et al.  Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy: a clinical randomised study. Acta Anaesthesiol Scand 1998;42545- 550
PubMed Link to Article
Dulguerov  PGysin  CPerneger  TVChevrolet  JC Percutaneous or surgical tracheostomy: a meta-analysis. Crit Care Med 1999;271617- 1625
PubMed Link to Article
Griggs  WMMyburgh  JAWorthley  LI A prospective comparison of a percutaneous tracheostomy technique with standard surgical tracheostomy. Intensive Care Med 1991;17261- 263
PubMed Link to Article
Heffner  JE Percutaneous tracheotomy: novel technique or technical novelty? Intensive Care Med 1991;17252- 253
PubMed Link to Article
Lawn  NDWijdicks  EF Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve 2000;23613- 616
PubMed Link to Article
Haymaker  WKernohan  JW The Landry-Guillain-Barré syndrome: a clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine (Baltimore) 1949;2859- 141
Link to Article
Marshall  J The Landry-Guillain-Barré syndrome. Brain 1963;8655- 66
Link to Article
McFarland  HRHeller  GL Guillain-Barré disease complex. Arch Neurol 1966;14196- 201
PubMed Link to Article
Moulin  DEHagen  NFeasby  TEAmireh  RHahn  A Pain in Guillain-Barré syndrome. Neurology 1997;48328- 331
PubMed Link to Article
Ravn  H The Landry-Guillain-Barré syndrome: a survey and clinical report of 127 cases. Acta Neurol Scand 1967;43(suppl 30)1- 64
PubMed
Winer  JBHughes  RACOsmond  C A prospective study of acute idiopathic neuropathy, I: clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51605- 612
PubMed Link to Article
Pandey  CKBose  NGarg  G  et al.  Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002;951719- 1723
PubMed Link to Article
Tripathi  MKaushik  S Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 2000;28655- 658
PubMed Link to Article
Rosenfeld  BBorel  CHanley  D Epidural morphine treatment of pain in Guillain-Barré syndrome. Arch Neurol 1986;431194- 1196
PubMed Link to Article
Burns  TMLawn  NDLow  PACamilleri  MWijdicks  EF Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve 2001;24963- 965
PubMed Link to Article
Zochodne  DW Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;171145- 1155
PubMed Link to Article
Sakakibara  RHattori  TKuwabara  SYamanishi  TYasuda  K Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;63649- 653
PubMed Link to Article
Ponec  RJSaunders  MDKimmey  MB Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999;341137- 141
PubMed Link to Article
Meythaler  JM Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil 1997;78872- 879
PubMed Link to Article
Pitetti  KHBarrett  PJAbbas  D Endurance exercise training in Guillain-Barré syndrome. Arch Phys Med Rehabil 1993;74761- 765
PubMed Link to Article
Herbison  GJJaweed  MDitunno  JF Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil 1983;64201- 205
PubMed
Johnson  PCFisher  CLLeach  C Hematological implications of hypodynamic states.  In: Murray  RH, McCally  M, eds. Hypogravic and Hypodynamic Environments. Washington, DC: National Aeronautics and Space Administration; 1971:27-34
Meythaler  JMKorkor  ABKumar  NANanda  TFallon  M Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome: successful therapy with combined calcitonin and etidronate. Arch Intern Med 1986;1461567- 1571
PubMed Link to Article
Meythaler  JMDeVivo  MJBraswell  WC Rehabilitation outcomes of patients who have developed Guillain-Barré syndrome. Am J Phys Med Rehabil 1997;76411- 419
PubMed Link to Article
Bernsen  RAJAMJacobs  HMDe Jager  AEJvan der Meché  FGA Residual health status after Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;62637- 640
PubMed Link to Article
Bernsen  RAJAMDe Jager  AEJSchmitz  PIMvan der Meché  FGA Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53409- 410
PubMed Link to Article
Merkies  ISSchmitz  PISamijn  JPvan der Meché  FGvan Doorn  PAEuropean Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Fatigue in immune-mediated polyneuropathies. Neurology 1999;531648- 1654
PubMed Link to Article
Krupp  LBLaRocca  NGMuir-Nash  JSteinberg  AD The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;461121- 1123
PubMed Link to Article
Karper  WB Effects of low-intensity aerobic exercise on one subject with chronic-relapsing Guillain-Barré syndrome. Rehabil Nurs 1991;1696- 98
PubMed Link to Article
Murray  TJ Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12251- 254
PubMed
Garssen  MPJSchmitz  PIMvan der Meché  FGAMerkies  ISJvan Doorn  PA Amantadine for treatment of fatigue after the Guillain-Barré syndrome (GBS), a double-blind, randomized, placebo controlled, cross-over trial. Neuromuscul Disord200212759 . Abstract
Wijdicks  EFMFletcher  DDLawn  DD Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology 2000;55452- 453
PubMed Link to Article
Pritchard  JMukherjee  RHughes  RAC The risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry 2002;73348- 349
PubMed Link to Article
Seyal  MZiegler  DKCouch  JR Recurrent Guillain-Barré syndrome following influenza vaccine. Neurology 1978;28725- 726
PubMed Link to Article
Hughes  RACChoudhary  PPOsborn  MRees  JHSanders  EACM Immunisation and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1996;191230- 1231
PubMed Link to Article
Pollard  JDSelby  G Relapsing neuropathy due to tetanus toxoid. J Neurol Sci 1978;37113- 125
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 61

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Critically ill Guillain Barre' syndrome. J Assoc Physicians India 1994;42(11):871-4.